About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

July! Decisive Month On Obesity Drug in US

by Nancy Needhima on April 11, 2012 at 11:36 PM
Font : A-A+

July! Decisive Month On Obesity Drug in US

Qnexa, the first obesity drug in over a decade, awaits US regulators' decision in July whether to approve extending the initial deadline by three months, the California-based drug-maker VIVUS said.

The extra time is a "standard extension period" offered by the US Food and Drug Administration in order to review additional risk management strategies that were submitted by the company, said a statement issued late Monday.

Advertisement

The new date for a decision is now set for July 17.

An advisory panel to FDA in February urged approval of Qnexa, after warning against its approval in 2010 due to safety concerns.

The panel voted 20-2 that the FDA should allow Qnexa on the market, saying the latest overall benefit-risk assessment supported its approval, but asking for more data on potential risks and how to avoid them.
Advertisement

For instance, some people who took high doses of the drug experienced increased heart rate. When taken by pregnant women it also boosted the risk of having a baby with cleft palate.

"The Qnexa REMS (risk evaluation and mitigation strategy) submission is comprehensive, with materials based on ongoing feedback from the FDA since our advisory committee meeting in February," said Leland Wilson, chief executive officer of VIVUS.

"We look forward to finalizing our REMS with the FDA while we move forward with our commercialization plans."

Qnexa combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can be used in conjunction with other drugs for weight loss.

Some doctors already prescribe the combination as an off-label use for helping patients manage their weight.

Studies have shown dieters could lose up to 10% of their weight when taking the drug, along with regular exercise and following a healthy diet.

The FDA does not have to follow the advice of the advisory panel, though it usually does.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
COVID Toes
International Yoga Day 2022 - 'Yoga for Humanity'
Wearable Devices Are Now Transforming Depression, Multiple Sclerosis, and Epilepsy Management.
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Bariatric Surgery Drug Toxicity Obesity Bulimia Nervosa Body Mass Index Signature Drug Toxicity Liposuction Battle of the Bulge Diabesity Hunger Fullness and Weight Control 

Most Popular on Medindia

Calculate Ideal Weight for Infants Drug Interaction Checker How to Reduce School Bag Weight - Simple Tips Blood Pressure Calculator Selfie Addiction Calculator Drug Side Effects Calculator A-Z Drug Brands in India Sinopril (2mg) (Lacidipine) Hearing Loss Calculator Blood Donation - Recipients

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use